Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pediatrix Medical (MD)

Pediatrix Medical Group names Mark Ordan CEO, succeeding James Swift, effective January 12

Neutral Impact 4 of 5 leadership Written later

Pediatrix Medical Group's board appointed Mark S. Ordan, a director and the company's Executive Chair, as chief executive officer effective January 12, 2025, succeeding Dr. James D. Swift. Dr. Swift's departure is treated as a termination without Cause, and Mr. Ordan's employment agreement sets a $1 million salary, a $2 million retention award and a 150% target bonus.

Key points

  • Mark S. Ordan appointed CEO effective January 12, 2025; Dr. James D. Swift steps down as CEO
  • Ordan's pay includes a $1 million salary, a $2 million one-time retention award and a target bonus of 150% of salary
  • Performance share award covers 640,000 shares, with vesting tied to stock price hurdles of 125%, 150% and 175% of the 20-day average close and a three-year anniversary
  • Ordan will remain Chair of the Board without additional board compensation

The filing

CompanyPediatrix Medical (MD)
Form8-K, current report
Filed with the SECJan 14, 2025, 4:30 PM ET
Accession number0001193125-25-006190

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 14, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.